A Multicentre, Non-interventional, Observational Study to Evaluate Safety and Efficacy of NovoSeven in Patients With Glanzmann's Thrombasthenia in Japan

Trial Profile

A Multicentre, Non-interventional, Observational Study to Evaluate Safety and Efficacy of NovoSeven in Patients With Glanzmann's Thrombasthenia in Japan

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Thrombasthenia
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 10 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 30 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jul 2014 According to a Novo Nordisk media release, eptacog alfa was approved by the US FDA for the perioperative management and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top